OMERO
LIVE

Serial Number

79238385

Owner

Glencoe Software Inc.

Attorney

Stacey J. Watson, Esq.

Filing Date

May 29, 2018

Add to watchlist:

No watchlists yet
View on USPTO

OMERO Trademark

Serial Number: 79238385 • Registration: 5802880

OMERO is a trademark filed by Glencoe Software Inc. on May 29, 2018. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Glencoe Software Inc. (13 trademarks)

800 5th Avenue #101-259

Entity Type: 03

Trademark Details

Filing Date

May 29, 2018

Registration Date

July 16, 2019

Published for Opposition

April 30, 2019

Goods & Services

Computer software, including computer software downloadable from the Internet, for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; data access and data management software tools for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable electronic publications in the nature of scientific journals, periodicals and newsletters relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof *

Business services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science, namely, management of biological and biomedical data and images for business enterprises; data processing services; all the aforesaid services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof *

Licensing of computer software for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof *

Design and development of computer software, software tools, data access tools and data management tools; computer programming; installation, maintenance and repair of computer software; design of computer websites and maintenance thereof; software as a service (SAAS) featuring software for the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; all the aforesaid services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof *

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Nov 6, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Nov 6, 2025 C75A
TEAS SECTION 71 & 15 RECEIVED
Nov 6, 2025 ES75
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Feb 26, 2025 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 23, 2024 INPR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 16, 2024 REM3
OTQR WITHDRAWAL FROM PUBLICATION
May 31, 2024 WDRL
AMENDMENT UNDER SECTION 7 - PROCESSED
Apr 22, 2024 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 16, 2024 APRE
TEAS SECTION 7 REQUEST RECEIVED
Sep 1, 2023 ES7R
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 22, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 1, 2019 FICS
FINAL DISPOSITION PROCESSED
Nov 1, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 16, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 16, 2019 R.PR
NOTIFICATION PROCESSED BY IB
May 3, 2019 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2019 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2019 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 17, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 17, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2019 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 26, 2019 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 5, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 5, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 5, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 5, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 27, 2019 TEME
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 27, 2019 CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 27, 2019 CHAN
ASSIGNED TO LIE
Feb 26, 2019 ALIE
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 21, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 13, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 13, 2019 REAP
REFUSAL PROCESSED BY IB
Oct 13, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 25, 2018 RFCS
REFUSAL PROCESSED BY MPU
Sep 25, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 21, 2018 RFCR
NON-FINAL ACTION WRITTEN
Sep 20, 2018 CNRT
ASSIGNED TO EXAMINER
Sep 17, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 18, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 9, 2018 REPR